Skip to main content

Table 4 Prognostic factors for progression-free survival

From: Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib

Variable

Univariate

Multivariate

p value

p value

Hazard ratio

95% CI

VAFmean-change, ≥0/< 0

< 0.001

0.002

8.4

2.3–31.2

Age, high/low

0.52

   

Sex, male/female

0.26

   

Dose, 12 mg/8 mg

0.92

   

BCLC, C/B

0.20

   

TNM staging, 4b/3 or 4a

0.28

   

T, 4/3 or less

0.05

   

M, 1/0

0.50

   

N, 1/0

0.35

   

Main tumor size, high/low

0.95

   

AFP, high/low

0.96

   

AFP, decrease/increase

0.56

   

DCP, high/low

0.03

0.13

2.3

0.8–6.7

ALBI, G2/G1

0.41

   
  1. CI confidence interval, VAF variant allele frequency, BCLC Barcelona Clinic Liver Cancer, TNM Tumor, Node, Metastasis, MVI macroscopic portal vein invasion, AFP alpha-fetoprotein, DCP des-gamma-carboxy pro-thrombin, ALBI albumin-bilirubin
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us